{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:33:42Z","timestamp":1767998022629,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.amjmed.2005.12.011","type":"journal-article","created":{"date-parts":[[2006,2,15]],"date-time":"2006-02-15T07:21:04Z","timestamp":1139988064000},"page":"9-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"S1","title":["Using Anticholinergics to Treat Overactive Bladder: The Issue of Treatment Tolerability"],"prefix":"10.1016","volume":"119","author":[{"given":"David R.","family":"Staskin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A.","family":"MacDiarmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2005.12.011_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.amjmed.2005.12.011_bib2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1046\/j.1464-410X.2003.04463.x","article-title":"The impact on health-related quality of life of stress, urge, and mixed urinary incontinence","volume":"92","author":"Coyne","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.amjmed.2005.12.011_bib3","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMra032662","article-title":"Management of overactive bladder","volume":"350","author":"Ouslander","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.12.011_bib4","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0090-4295(01)00986-4","article-title":"Health-related quality of life among adults with symptoms of overactive bladder","volume":"57","author":"Liberman","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.amjmed.2005.12.011_bib5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","article-title":"Antimuscarinics for treatment of overactive bladder","volume":"3","author":"Andersson","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.amjmed.2005.12.011_bib6","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3949\/ccjm.69.10.761","article-title":"The newer antimuscarinic drugs","volume":"69","author":"Appell","year":"2002","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.amjmed.2005.12.011_bib7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0022-5347(05)68810-6","article-title":"Once daily controlled versus immediate release oxybutynin chloride for urge incontinence","volume":"161","author":"Anderson","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.amjmed.2005.12.011_bib8","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","article-title":"Tolterodine once-daily","volume":"57","author":"Van Kerrebroeck","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.amjmed.2005.12.011_bib9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0090-4295(03)00356-X","article-title":"Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence","volume":"62","author":"Dmochowski","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.amjmed.2005.12.011_bib10","first-page":"718","article-title":"Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence","volume":"95","author":"Versi","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.amjmed.2005.12.011_bib11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0090-4295(99)00259-9","article-title":"Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence","volume":"54","author":"Gleason","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.amjmed.2005.12.011_bib12","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/01.ju.0000173076.93737.d5","article-title":"Efficacy and safety of extended-release oxybutynin for the treatment of urge incontinence","volume":"174","author":"MacDiarmid","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.amjmed.2005.12.011_bib13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11934-003-0021-3","article-title":"Muscarinic receptors","volume":"4","author":"Scarpero","year":"2003","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.amjmed.2005.12.011_bib14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0031-6997(24)01362-0","article-title":"International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors","volume":"50","author":"Caulfield","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.amjmed.2005.12.011_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s003450100226","article-title":"Which muscarinic receptor is important in the bladder?","volume":"19","author":"Yamanishi","year":"2001","journal-title":"World J Urol"},{"key":"10.1016\/j.amjmed.2005.12.011_bib16","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1464-410X.2005.05454.x","article-title":"A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder","volume":"95","author":"Chapple","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.amjmed.2005.12.011_bib17","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0022-5347(05)68951-3","article-title":"Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity","volume":"161","author":"Millard","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.amjmed.2005.12.011_bib18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s11934-003-0025-z","article-title":"Overactive bladder","volume":"4","author":"MacDiarmid","year":"2003","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.amjmed.2005.12.011_bib19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0025-6196(11)62382-3","article-title":"Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder","volume":"76","author":"Appell","year":"2001","journal-title":"Mayo Clin Proc"},{"issue":"suppl 3A","key":"10.1016\/j.amjmed.2005.12.011_bib20","doi-asserted-by":"crossref","first-page":"24S","DOI":"10.1016\/j.amjmed.2005.12.013","article-title":"Pharmacologic management of overactive bladder","volume":"119","author":"Staskin","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2005.12.011_bib21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/78.6.687","article-title":"Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder","volume":"78","author":"Diokno","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjmed.2005.12.011_bib22","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.ajog.2005.03.036","article-title":"Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles","volume":"192","author":"Chu","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.amjmed.2005.12.011_bib23","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1097\/01.ju.0000127742.73136.0c","article-title":"Trospium chloride improves overactive bladder symptoms","volume":"171","author":"Zinner","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.amjmed.2005.12.011_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00210-002-0554-x","article-title":"M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland","volume":"366","author":"Ikeda","year":"2002","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.amjmed.2005.12.011_bib25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1464-410X.2004.04561.x","article-title":"Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.amjmed.2005.12.011_bib26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1464-410X.2004.04606.x","article-title":"Randomized, double-blind placebo-and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.amjmed.2005.12.011_bib27","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/01.ju.0000140729.07840.16","article-title":"Randomized, double-blind placebo-controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder","volume":"172","author":"Cardozo","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.amjmed.2005.12.011_bib28","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2004.01.008","article-title":"Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder","volume":"45","author":"Haab","year":"2004","journal-title":"Eur Urol"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305011915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305011915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:41:06Z","timestamp":1757580066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934305011915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S0002934305011915"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.12.011","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using Anticholinergics to Treat Overactive Bladder: The Issue of Treatment Tolerability","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}